Business Context and Reporting Period
This Form 8-K was filed by Illumina, Inc. on February 7, 2016. The report addresses a specific corporate governance event regarding the departure of a director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to Item 5.02 and does not contain financial statements or performance data.
Material Changes
Departure of Director: On February 7, 2016, Jeffrey T. Huber resigned from the Board of Directors. This resignation was made in compliance with Illumina's governance practices.
Reason for Departure: Mr. Huber resigned to invest in and serve as the Chief Executive Officer and a member of the board of directors of GRAIL, Inc.
Relationship to Parent Company: GRAIL is identified as Illumina's majority-owned subsidiary, formed to enable cancer screening from a blood test powered by Illumina sequencing technology.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on future performance, or specific risk factors beyond the context of the director's transition to a subsidiary role.
Investor Verification Checklist
- Verify the exact ownership percentage Illumina holds in GRAIL, Inc.
- Confirm if Jeffrey T. Huber's departure triggers any changes in executive compensation or board committee assignments.
- Review subsequent filings for updates on GRAIL's operational progress or financial integration with Illumina.